Turn Therapeutics Inc(TTRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.29 | Insider Own | 63.78% | Shs Outstand | 29.8M | Perf Week | 26.02% |
| Market Cap | 0.38B | Forward P/E | - | EPS next Y | 2.5% | Insider Trans | - | Shs Float | 10.8M | Perf Month | 20.4% |
| Enterprise Value | 0.37B | PEG | - | EPS next Q | -0.09 | Inst Own | 4.07% | Short Float | 1.23% | Perf Quarter | 116.55% |
| Income | -0.01B | P/S | - | EPS this Y | -233.33% | Inst Trans | 56.57% | Short Ratio | 1.53 | Perf Half Y | 240.67% |
| Sales | 0.00B | P/B | 550.3 | EPS next 5Y | - | ROA | -76.99% | Short Interest | 0.13M | Perf YTD | 222.08% |
| Book/sh | 0.02 | P/C | 36.74 | EPS past 3/5Y | 29.26% - | ROE | -543.37% | 52W High | -52.11% ($26.50) | Perf Year | - |
| Cash/sh | 0.35 | P/FCF | - | Sales past 3/5Y | - | ROIC | -124.96% | 52W Low | 393.76% ($2.57) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -117.37% | Gross Margin | - | Volatility(W/M) | 14% 9.14% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.19 | EPS Q/Q | -117.74% | Profit Margin | - | RSI (14) | 66.15 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.19 | Sales Q/Q | - | SMA20 | 21.6% ($10.44) | Beta | - | Target Price | $26 |
| Payout | - | Debt/Eq | 8.87 | Earnings | 2026/8/12 | SMA50 | 31.38% ($9.66) | Rel Volume | 1.53 | Prev Close | $13.38 |
| Employees | 2 | LT Debt/Eq | 8.8 | EPS/Sales Surpr. | -900% - | SMA200 | 130.1% ($5.51) | Avg Volume(3M) | 0.09M | Price | $12.69 |
| IPO | 2025/10/8 | Option/Short | No/Yes | Trades | 1826 | Volume | 132,777 | Change | -5.16% |
Company
TTRX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Turn Therapeutics (TTRX) is a clinical-stage biotech company developing treatments for dermatological, advanced wound, and infectious diseases. The company holds clinical programs for conditions such as eczema and onychomycosis, along with its PermaFusion delivery platform, and is headquartered in the US, pursuing a commercialization strategy through medical distribution partnerships.
Over the past 1 year, roughly in the middle
52% below its 1-year high.
TTRX has weak earning power
Review management risk carefully before investing
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -233.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 4.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VTI 0.00%It ranks #4 in the industry
Based on market cap of $378M.
TTRX $378M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is TTRX?
TTRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TTRX?
The market cap of TTRX is approximately $378M, ranking 3,469 within its sector.
What is the 52-week high and low for TTRX?
TTRX has recorded a 52-week high of $26.50 and a low of $2.57.
